新日本科学（2395） – Presentation materials for the Fiscal Year Ended March 31, 2022

The Fiscal Year Ended March 31, 2022Financial Results PresentationMay 10, 2022SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.(TSE PRIME: 2395)Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Table of Contents１．FY2022/3 Overview & Future Outlook２．Outline of Consolidated Financial Results３．Business TopicsCRO (Preclinical) BusinessCRO (Clinical)/TR/Medipolis Business４．Q&AP. 2P. 5P. 13P. 18P. 25Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.1１．FY2022/3 Overview & Future OutlookRyoichi Nagata, MD, PhD, FFPMRepresentative Chairman and President, CEO and CHOCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.2Summary1. FY2022/3 Results Various measures and management efforts finally starting to pay off and bear fruit Achieved double-digit increase in revenue and profits, driven by the industry-wide trend of accelerating R&D activities targeting new drug modalities Realized record-high profits, orders received and dividend ２. FY2023/3 Forecasts & Future Direction Expect two-digit growth in revenue and profit as favorable business environment continues Promote “time-value creation” that help maximize benefits in clients by leveraging DX and robotization Launch P1 clinical trial for proprietary nasal drug delivery platform technology Plan over ¥5 bn investment in facilities this fiscal year to further accelerate our sustainable growth ３．Initiatives to Enhance Corporate Value : SDGs/ESG Focus on employees’ happiness: improvement of compensation system, better disclosure of promotional eligibility, and promotion of job satisfaction reform, etc. Selected for Nadeshiko Brand 2021 for the 1st time and for Health & Productivity Management Outstanding Organization (large enterprise category (White 500)) for the 6th consecutive year. Aim to realize “Carbon-Neutral” by 2030, by leveraging a vast land and forest in Medipolis Ibusuki, Kagoshima Plan to publish the first Integrated Report which brings together SNBL’s material financial/nonfinancial information this autumn.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.3Initiatives to Enhance Corporate Value : SDGs/ESG＜Materiality and Sustainability Focus at SNBL Group＞■Forest in Medipolis Ibusuki, Ibusuki City, Kagoshima Pref.＜Corporate Philosophy＞We are a company that values the environment, life, and people.＜SNBL Corporate Slogan＞I am happy, you are happy, everyone is happy.Source：”Sustainability Report 2021” (https://www2.tse.or.jp/disc/23950/140120211025416124.pdf)■ Geothermal power plant in Medipolis IbusukiCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.4２．Outline of Full-Year Consolidated Financial ResultsShinji NitandaSenior Managing Executive Officer and CFOCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.5FY2022/3 Financial Results HighlightsRecord high profits achieved at Operating Profit, Ordinary Profit and Profit Attributable to Owners of Parent. FX gains of JPY 1.37 bn resulted in Ordinary Profit significantly exceeded the forecasts announced on 2/2/2022.(100 million of yen)(単位：億円)FY2021/3ResultsPrevious forecasts(2/2/2022)ResultsFY2022/3Changes against previous forecastsYoyNet salesOperating ProfitOrdinary ProfitOrdinary Profit(excl. FX gain/loss)Profit Attributable to Owners of ParentCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.6売上高151.1179.0177.4-1.5+26.317.5%営業利益25.241.041.9+0.9+16.665.9%経常利益36.456.370.7+14.4+34.394.2%経常利益（為替差損益影響を除く）34.051.357.0+5.6+23.067.6%親会社株主に帰属する当期純利益36.658.071.2+13.2+34.694.6%2021年3月期2022年3月期前回予想（2022/2/2開示）実績前回予想比前期比Yoy Comparison of Consolidated Operating Profit & Loss CRO businessPreclinicalClinical (incl. PPD-SNBL)TranslationalResearch businessMedipolis business (power generation & hospitality)OtherOperating profittotalFY2022/3 FY2021/3 Yoy changes +16.725.2▲0.2▲0.4+0.4+0.1(100 million of yen)41.9¥1.66bn2021年3月期FY21/3前臨床PreclinicalClinical (incl. 国内臨床PPD-SNBL)トランスTranslationalレーショナルResearchリサーチMedipolis(power メディポリスgeneration & hospitality)その他Other2022年3月期FY22/3Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.7前臨床事業国内臨床事業2022年3月期実績51.00.7-7.4-0.1-2.341.92021年3月期実績34.30.9-7.0-0.5-2.525.2前期比増減額+16.7-0.2-0.4+0.4+0.1+16.6営業利益合計CRO事業トランスレーショナルリサーチ事業メディポリス事業その他Yoy Comparison of Consolidated Ordinary Profit & Loss CRO businessPreclinicalClinical (incl. PPD-SNBL)TranslationalResearch businessMedipolis business (power generation & hospitality)Foreign exchange gain and lossOtherOrdinary profit totalFY2022/3 FY2021/3 Yoy changes (100 million of yen)+11.4+0.713.757.0¥3.43 bn+3.7 ▲0.4+0.4+18.536.4FY2021/3 results: 1.90 weaker yen ⇒ FX gain of 230 million yen (FX rate as of 31/03/2021: JPY/USD 110.71)FY2022/3 results: 11.70 weaker yen ⇒FX gain of 1.37 billion yen(FX rate as of 31/03/2022: JPY/USD 122.41)2021年3月期FY21/3PreclinicalClinical (incl. PPD-SNBL)TranslationalResearchMedipolis(power generation & hospitality)FX gainand lossOtherFY22/3Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.8前臨床事業国内臨床事業(新日本科学PPD含む)2022年3月期実績52.813.7-7.4-0.113.7-2.070.72021年3月期実績34.310.0-7.0-0.52.3-2.736.4前期比増減額+18.5+3.7-0.4+0.4+11.4+0.7+34.3経常利益合計CRO事業トランスレーショナルリサーチ事業メディポリス事業為替差損益その他FY2023/3 ForecastsRecord high Operating Profit for the forth consecutive year expected.Excluding FX impact, positive growth of Ordinary Profit is also in projection.(100 million of yen)1. Preclinical CRO businessSales and profits are expected to increase by ¥1.76 bn and ¥1.29 bn respectively, yoy.FY2023/3FY2021/3ResultsFY2022/3ResultsFull-yearForecastsChanges against previous forecastsNet salesOperating ProfitOrdinary ProfitOrdinary Profit(excl. FX gain/loss)Profit Attributable to Owners of Parent2. TR businessSpending on a clinical study for a nasal neurodegenerative disease rescue medication is planned. 3. FX gain and loss (non-operating profit/loss) In relation to loans to subsidiaries, FX valuation decrease of ¥1.37 bn yoy is expected: – FY2022/3 +¥1.37bn- FY2023/3 ±¥0- FX assumption: JPY/USD122.41cf. FX sensitivity – 1 yen fluctuation Sales: 44 million JPY/USD Operating Profit: 30 million JPY/USDNon-operating Profit: 120 million JPY/USD4. Extraordinary profitIn FY2022/3, an extraordinary profit of ¥1.36 bn from change in equity in a subsidiary in China was recorded.5. Corporte taxDecrease of retained losses will result in less tax shield. Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.9売上高151.1177.4196.0+18.510.4%営業利益25.241.950.0+8.019.2%経常利益36.470.760.0△10.7-15.2%経常利益（為替差損益影響を除く）34.057.060.0+2.95.1%親会社株主に帰属する当期純利益36.671.243.0△28.2-39.7%2022年3月期2023年3月期前期比2021年3月期通期業績予想Comparison of FY2023/3 Consolidated Operating Profit & Loss Forecasts against FY2022/3 ResultsCRO businessPreclinicalClinical (incl. PPD-SNBL)TranslationalResearch businessMedipolis business (power generation & hospitality)OtherOperating profit totalFY2023/3 forecast FY2022/3 results Yoy changes 41.9▲0.7▲2.8+13.0▲0.8▲0.7(100 million of yen)¥800 mn50.0FY22/3ResultsPreclinicalClinical (incl. PPD-SNBL)TranslationalResearchMedipolis(power generation & hospitality)Otherその他FY23/32023年3月期ForecastCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.10前臨床事業国内臨床事業2023年3月期予想64.00.0-10.2-0.9-2.950.02022年3月期実績51.00.7-7.4-0.1-2.341.9前期比増減額+13.0-0.7-2.8-0.8-0.7+8.0営業利益合計CRO事業トランスレーショナルリサーチ事業メディポリス事業その他Comparison of FY2023/3 Consolidated Ordinary Profit & Loss Forecasts against FY2022/3 ResultsCRO businessPreclinicalClinical (incl. PPD-SNBL)TranslationalResearch businessMedipolis business (power generation & hospitality)Foreign exchange gain and lossOtherOrdinary profit totalFY2023/3 forecast FY2022/3 results Yoy changes (100 million of yen)Excluding FX impact, Profit increased by ¥290 mn ▲4.8+12.6▲2.8▲0.813.7▲13.7▲1.2¥1.07 bn57.0FY2022/3 results: ¥11.70 weaker yen against USD ⇒ FX gain of 1.37 billion yenFY2023/3 assumption: ¥122.41 yen against USD 60.0FY23/32022年3月期Results前臨床Preclinical国内臨床Clinical (incl. (新日本科学PPDPPD-SNBL)含む)トランスTranslationalレーショナルResearchリサーチMedipolis(power generation & hospitality)FX gain為替差損益and lossOtherその他FY23/32023年3月期ForecastCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.11前臨床事業国内臨床事業(新日本科学PPD含む)2023年3月期予想65.48.9-10.2-0.90.0-3.260.02022年3月期実績52.813.7-7.4-0.113.7-2.070.7前期比増減額+12.6-4.8-2.8-0.8-13.7-1.2-10.7経常利益合計CRO事業トランスレーショナルリサーチ事業メディポリス事業為替差損益その他CAPEXCRO (preclinical) Business and Medipolis (power generation) Business will be key focus areas in FY2023/3.(100 million of yen)OthersMedipolisCROTranslational ResearchFY2021/3FY2022/3FY2023/3 EFY2021/3FY2022/3FY2023/3Forecasts Yoy CAPEXDepreciationCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.125.010.741.53.31.811.01.74.44.110.217.057.00.010.020.030.040.050.060.02021年3月期2022年3月期2023年3月期その他メディポリス事業トランスレーショナルリサーチ事業CRO事業通期業績予想前期比設備投資10.217.057.0+40.0減価償却費11.811.714.1+2.42021年3月期2022年3月期2023年3月期３．Business Topics: CRO (Preclinical) BusinessHideshi Tsusaki, DVM, PhD Senior Executive Director, President of Preclinical Business and Global BDCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.13CRO Business: ContractContract Amount(x100M JPY)Contract AmountBacklogBacklog(x100M JPY)194.92002502001501000132.7106.0112.974.2223.950102.9135.7131.9152.7150100500FY2017’18/3通期FY2018’19/3通期FY2019’20/3通期FY2020’21/3通期FY2021’22/3通期Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.14CRO Business: Contract from OverseasContract Amount(x100M JPY)Europe & the USAsiaRatio of Contract from OverseasRatio of Contract from Overseas8070605040302010027.5%30%61.417.520%43.910%0%20.5%31.314.716.611.2%12.6%11.53.67.917.14.212.813.5%17.86.311.4’18/3通期FY2017’19/3通期FY2018’20/3通期FY2019’21/3通期FY2020’22/3通期FY2021Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.15CRO Business: Contract by drug modality- Number of drug candidates contracted (excluding low molecules)Number in 2021 was almost equal to that in 2020. An increase in vaccine and peptide was noted.- Number of studies in drug candidates contracted (excluding low molecules)Number of studies (719) in 2021 increased by 43% compared with that in 2020. Number of GLP studies (253) in 2021 increased by 51%. An increase in antibody and nucleic acid was noted.Guideline on nonclinical safety assessment in nucleic acid drugs (2020)Whitepaper on quality management and nonclinical safety assessment in nucleic acid drugs (2016)Ordinance on conduct of nonclinical studies in safety of regenerative medicines (2014)Paper on nonclinical safety studies for therapeutic peptide vaccine (2014)Guidance on peptide vaccine for cancer treatment (2012)Guideline on nonclinical studies in vaccine for infection disease(2010) LBNSybdetcartnocsetaddnacgurd fo# i Bacteria/VirusCellNucleic acidVaccinePeptideProteinAntibodyYearCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.16CRO Business: Our Strength in NHP studiesDistinguished NHP Supply Chain- Our own control in breeding, raising, transporting, and stably assigning to a study within the SNBL Group- The business model that we uniquely established from 1990’s at the first time in the globeWorldwide Shortage of NHPs due to Covid-19 Pandemic- Active global development of multiple drug modalities (Increase in demand)- Continuing suspension of NHP exports from the dominant supply country, China (limitation in supply)- No adverse influence in SNBL because of our established own supply chainFurther Enhancements of the NHP Supply Chain and of Capacity in Study Conduct- Increasing the breeding capacity in our Cambodian facility and enhancing NHP procurement routes- Increasing and enhancing the breeding capacity within Japan facility- Adding the research facility including NHP study rooms and actively recruiting research staffCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.17３．Business Topics : CRO(Clinical)/TR/Medipolis BusinessesKen Takanashi, USCPA Executive Vice President and COOIchiro Nagata, MD, PhD, MMH, MBAExecutive Director Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.18Ⅰ. CRO (Clinical) Business In the midst of overcoming the global challenge of pandemics, the importance of global clinical trials has been increasing in recent years to improve cost efficiency while overcoming medical drug lag Our partner, PPD Group, has been steadily growing its business as a highly reliable global CRO with the capability to conduct simultaneous clinical trials in approximately 50 countries. Thermo Fisher Scientific, one of the world’s leading medical device companies has acquired the PPD Group to develop a global strategy of full-line services. This acquisition is expected to have a synergistic effect on order acceptance by mutually complementing the customer networks of PPD Group and Thermo Fisher Scientific. PPD-SNBL K.K., which SNBL owns 40% of its stocks and the sole joint venture of PPD Group, has achieved a high employee retention rate by incorporating elements of Japanese management and has expanded its business. (After 4 years of its establishment, it was selected as one of the top 5 growing companies to attract workers in 2019 by Randstad Japan) The company is receiving orders for studies in areas that meet recent development needs, such as malignant tumors, infectious diseases, central nervous system, cardiovascular system, and metabolism/endocrine system. In response to the steadily growing order, the company is strengthening its human resources.(million yen)10,0007,712 7,5005,0002,5000PPD-SNBL Business Performance and SNBL’s Equity Method Investment Gain10,215 10,724 8,808 701 553 391 1,463 1,796 888 2,447 1,691 846 2,678 2,727 1,258FY2018FY2019FY2020FY2021RevenueOPNPSNBL’s equity method investment gainCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.19Ⅱ.TR Business–SNBL Nasal Drug Delivery Platform Technology and Its ApplicationsSNBL’s Proprietary Nasal Drug Delivery SystemNasal Drug Carrier Muco-adhesive power carrier and specific optimizations for each drug characteristic Clinical and non-clinical experiences with candidate products for the systemic absorptionNasal Delivery Device User-friendly Light-weight and compact Complete and consistentdelivery Low cost Specific design for each nasal applicationFor Systemic Absorption• Drug absorption via the dense microvascular network • Beneficial for any treatment requiring fast onset of action or bypass of first-pass metabolism, and for patients with difficulty swallowing oral medication• Excellent clinical safety profile in thousands of subjects• Out-licensed the nasal migraine drug to Satsuma Pharm.• On-going clinical P1 study for the candidate rescue product for neurodegenerative disorder by SNLD, Ltd. a spin-out subsidiary.For Nose-to-Brain Delivery• Drug delivery directly from the olfactory region to the brain• Beneficial technology for drugs which are do not or difficult to pass the BBB• Reduce systemic toxicity• Exploring drug candidates for developmentFor Vaccination• First-line defense with mucosal immunity• Second-line defense with systemic immunity • Cross protection (protection against mutant strains)• Aiming to demonstrate ideal application to respiratory infectious diseases. Such as COVID-19 and influenza. Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.blood vesselAPI or vaccinedrug carriernasal mucosanasal cavityⅡ. TR Business-Important investees-SatsumaPharmaceuticals, Inc.- Established in the U.S. in June 2016 as a licensee of SNBL proprietary nasal drug delivery technology with limited application for nasal migraine drug (DHE)- Listed on Nasdaq in September 2019, raising funds mainly from U.S. institutional Specialty Pharma for Nasal Migraine Drug investors]- Currently conducting Phase 3 pivotal study (efficacy/safety) in the U.S. (NDA submission is planned in the 1Q of 2023)Income from license (royalties on sales) expected after launch — SNBL owns 8.9% of the company stocksDeveloping nucleic acid medicines for genetic diseases by a platform technology of a stereocontrolled synthesis- Spin-out from the company established in Singapore in 2012 which was integrated from a SNBL subsidiary in the U.S. established in 2009 with a professor from Harvard University, and the one in Japan established in 2008 with a professor from the University of TokyoListed on Nasdaq in November 2015, raising funds mainly from US institutional investors– Clinical trials for three programs (Huntington’s disease, ALS/FTD, and Duchenne muscular dystrophy) by the latest stereocontrol synthesis technology has been underway since 2021- A development program utilizing its own genome editing (ADAR) technology (AATD) – Commercialization, including partnering, is being considered to utilize in-house GMP is also underwaymanufacturing capabilities. – SNBL owns 9.1% of the company stocksCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.21Ⅱ.TR Business: Business OverviewBusiness Development Platform• Gemseki mediates drug and delivery technology candidates between in and out-licensors globally and supports a smooth and efficient drug development.Venture Capital Investment•In addition to our business development platform, we act as a developmental partner of domestic and international clients who are committed to their growth and success within the life science business with investment and business incubation system.• We can support by using an abundant drug development experience and a strong global network within the SNBL Group.NameGemseki Investment Limited PartnershipFund Total1.1 Billion JPYOperation Period 10 yearsEstablishmentAugust, 2020Target andPolicyWe widely target within the drug development and healthcare field from drug candidates to early, middle, and later stages.Support system to investee companyCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.22Ⅲ. Medipolis Business – Hospitality (AMAFURU & Co.)At AMAFURU＆Co., we are involved in facility management within Wellness Resort Medipolis Ibusuki. As the affinity of the group as a whole, we operate 3 hotel business with our main concept as “Wellbeing of the People”; in other words, the realization of the overall health.Healing Resort AMAFURUWe provide Japanese hospitality to guests with the 3 pillars of wellness, nature, and luxury.Retreat Resort Ibusuki BayhillsWith the concept of “A second house within nature”, we provide a retreat and workcation service to look back at yourself.Medical Resort HOTEL FresiaWe provide a comfortable and relaxing environment for patients receiving treatment at the Medipolis Proton Therapy and Treatment Center and their family.Medipolis IbusukiHOTEL FresiaCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.23Ⅲ. Medipolis Business – Sustainable Development Company ~Toward the Achievement of SDGs ~■ Geothermal Power Generation

1. Nearly zero CO2 emission and excellent environmental compatibilityA base-load power source capable of stable power generation2.3.Japan has the third largest amount of worldwide geothermal power resources4. Multi-stage energy utilization (e.g. the use of hot water after power generation)Increasing demand of geothermal power generation is expected toward the Japanese government’s goal of achieving carbon neutrality by 2050.【Geothermal Power Plant in Medipolis Ibusuki】• Our binary geothermal power plant rated at 1,580 kW has been operating since February 2015.•All of the generated electricity is sold under the FIT Law, providing us a stable income.Average operating income (as power generation division): 182 million yenAverage sales of electricity per annum (average over the past 3 years): 10,471k kWh*(*Approx. 55% of our annual power consumption)Average equipment utilization rate (average for the past 3 years): 75.7%••Surplus steam from the power plant is used for greenhouse cultivation, heating of swimming pools, and heating of facilities, reducing CO2 emissions through multi-stage energy utilization.• We are working on geothermal power generation by the hot spring water currently used for bathing at our hotel. We aim the system to start functioning within this year.Planning a joint study with a University to investigate the possibility of CCS (Carbon Dioxide Capture and Storage) within our site.■ Seedling Production of Glass Eels• We conduct research on the artificial seedling production of glass eels, in order to protect the natural resources of Japanese eels, which are becoming increasingly depleted, and to contribute to the local community (Kagoshima Prefecture is the number one supplier of Japanese eels in Japan).Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.24Cautionary Notes1.2.Projected results are based on information available to the Company at the time of writing, as well as certainassumptions judged by the Company to be reasonable. Various risks and uncertain factors could cause actual resultsto differ materially from these projections. This material does not constitute a solicitation of application to acquire oran offer to sell any security in Japan or elsewhere. This material is presented to inform stakeholders of the views ofSNBL’s management but should not be relied on solely in making investment and other decisions. You should rely onyour own independent examination of us before investing in any securities issued by our company. SNBL shall acceptno responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of targetfigures or any other use of this material.Information about pharmaceutical products (including products currently in development) included in this material isnot intended to constitute an advertisement nor medical advice.3. The presentation slides are based on “Summary of Consolidated Financial Results for the Fiscal Year Ended March 31,2022 (Japanese GAAP).“ Figures rounded to the nearest 100 million JPY and percentage to one decimal place.4. This English presentation was translated from the original Japanese version. In the event of any inconsistencybetween the statements in the two versions, the statements in the Japanese version shall prevail.＜IR Inquiries＞Shin Nippon Biomedical Laboratories, Ltd. IR & Corporate CommunicationsPhone：E-mail：Website：+81 03-5565-6216ir@snbl.co.jphttps://www.snbl.co.jpCopyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.25I am happy, you are happy, and everyone is happy.SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.(TSE PRIME: 2395)Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.26